MDR-TB has new drug foe after fast-track approval

  • Voelker R
  • 21

    Readers

    Mendeley users who have this article in their library.
  • 18

    Citations

    Citations of this article.

Abstract

MDR-TB “poses a serious health threat throughout the world, and [bedaquiline] provides much-needed treatment for patients who don't have other therapeutic options,” said Edward Cox, MD, MPH, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, in a statement.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Rebecca Voelker

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free